Screener
Beam Therapeutics BEAM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -226.6%+451pp | -274.6%+380pp | -837.1%— | -739.9%— | -677.5%— | |
| Returns | ||||||
| Return on invested capital | -39.4%+16.1pp | -44.9%+17.6pp | -59.3%— | -54.2%— | -55.5%— | |
| Efficiency | ||||||
| Asset turnover | 0.1×+0.1× | 0.1×+0.1× | 0×-0.2× | 0×-0.2× | 0×-0.2× | |
| Liquidity | ||||||
| Current ratio | 17×+8.2× | 13.1×+8.3× | 6×+0.3× | 6.8×+0.9× | 8.8×+2.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.1× | 0.1×-0.1× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $11.28-12.2% | $12.52+40.5% | $9.42-1.9% | $10.26-1.1% | $12.84+14.8% | |
| Valuation | ||||||
| Market capitalization | $2.52B-2.7% | $2.81B+37.0% | $2.46B+21.6% | $1.72B-10.6% | $1.95B-27.7% | |
| Price / sales | 15.4×-31.1× | 20.1×-12.2× | 44.1×+38.3× | 28.6×+23.1× | 30.7×+23.2× | |
| Price / book | 2.2×-0.5× | 2.3×-0.5× | 2.5×0.0× | 1.6×-0.6× | 1.7×-1.2× |
FAQ
- Where do Beam Therapeutics's ratios come from?
- Every ratio is computed from Beam Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
